Guardant Health, Inc. (GH) Q3 2025 10-Q Quarterly Report
Guardant Health, Inc. (GH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Guardant Health, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No new risk factors added this quarter; no material changes since fiscal 2024 10-K filing
- • Most materially updated risk: none reported, risk factors unchanged since 2024 10-K
Guardant Health, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$265M
▲ +38.5% YoY▲ +14.3% QoQ
Net Income
-$93M
▲ +13.9% YoY▲ +7.2% QoQ
Operating Margin
-37.3%
▲ +2395bp YoY▲ +852bp QoQ
Net Margin
-35.0%
▲ +2131bp YoY▲ +808bp QoQ
ROE
26.2%
Total Assets
$1.3B
EPS (Diluted)
$-0.75
▲ +14.8% YoY▲ +6.3% QoQ
Operating Cash Flow
-$35M
▲ +30.6% YoY▲ +41.3% QoQ
Source: XBRL data from Guardant Health, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Guardant Health, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.